Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction

Amarin Corp. PLC

www.amarincorp.com

Latest From Amarin Corp. PLC

Bookmark
  • News

Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD

By Bridget Silverman

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Complete Response Letters
Bookmark
  • Analysis

Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks

By Mandy Jackson

Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.

Financing Business Strategies
Bookmark
  • News

An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

By Jessica Merrill and Mandy Jackson

The US FDA informed the company it will convene an advisory committee meeting to review the REDUCE-IT sNDA for the proprietary fish oil pill, delaying the approval by at least three months and surprising investors.

Advisory Committees Cardiovascular
Bookmark
  • News

Amarin Critic's Petition Counters Its Bid To Stop Some Omega-3 Supplement Sales

By Malcolm Spicer

"In a bid to have the right to purchase high-purity omega-3 supplements stripped from US consumers, Amarin attempted to circumvent the jurisdiction granted by Congress" to FDA, says Medical Research Collaborative in petition. The author also has reviewed Amarin's business results and has been critical of its stability.

Dietary Supplements Regulation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By